A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer. Cancer Invest 1997;15(4):311-7
Date
01/01/1997Pubmed ID
9246151DOI
10.3109/07357909709039731Scopus ID
2-s2.0-0030797719 (requires institutional sign-in at Scopus site) 22 CitationsAbstract
The management of hormone-refractory metastatic prostate cancer remains a therapeutic dilemma. We report the results of a phase II trial with deferoxamine administrated at a dose of 50 mg/kg (maximum dose 5 g) administered intravenously over 8 hr daily, repeated for 5 days at 4-week intervals for 2 courses. Fourteen patients with advanced hormone-refractory prostate cancer were treated and 28 courses were delivered. Essentially no toxicity was observed. Using combined clinical and prostate-specific antigen (PSA) criteria. 13 of 14 patients had disease progression. However, 9 of 14 patients had stable measurable or evaluable disease and progressed solely based on PSA criteria. Deferoxamine in this dose and schedule has no activity in hormone-refractory prostate cancer. Further investigation of the effect of deferoxamine on PSA production/expression is warranted.
Author List
Dreicer R, Kemp JD, Stegink LD, Cardillo T, Davis CS, Forest PK, See WAMESH terms used to index this publication - Major topics in bold
AdenocarcinomaAged
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Creatinine
Deferoxamine
Drug Resistance, Neoplasm
Humans
Hydroxyproline
Infusions, Intravenous
Lung Neoplasms
Lymphatic Metastasis
Male
Methylhistidines
Middle Aged
Pelvis
Prostatic Neoplasms
